Our goal is to begin to display how several biomarkers in development (e.g., neurofilament light chain (NfL), phosphorylated neurofilament heavy chain (pNfH), TDP-43 aggregates, mitochondrial stress markers, inflammatory markers, etc.)are changing our understanding of ALS and ALS dynamics. This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.